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Epidemiologically-related traits may share genetic risk factors and pleiotropic 
analysis could identify individual loci associated with these traits. Because of 
their shared epidemiological associations, we conducted pleiotropic analysis of 
genome-wide association studies of lung cancer (12,160 lung cancer cases and 
16,838 controls) and cardiovascular disease risk factors (blood lipids from 
188,577 subjects, type 2 diabetes from 148,821 subjects, body mass index from 
123,865 subjects, and smoking phenotypes from 74,053 subjects). We found that 
6p22.1 (rs6904596, ZNF184) was associated with both lung cancer (P=5.5x10-6) 
and blood triglycerides (P=1.39x10-5). We replicated the association in 6,097 lung 
cancer cases and 204,657 controls (P=2.4×10-4) and in 71,113 subjects with 
triglycerides data (P=0.011). rs6904596 reached genome-wide significance in 
lung cancer meta-analysis (odds ratio=1.15, Pcombined=5.2x10-9). The large sample 
size provided by the lipid GWAS data and the shared genetic risk factors 
between the two traits contributed to the uncovering of a hitherto unidentified 
genetic locus for lung cancer. 
 
 
Genetic heritability of lung cancer is estimated to be 14% [1], but only a few genetic 
risk loci have been identified to date in genome-wide association studies (GWAS) of 
lung cancer in Europeans [2]. Epidemiological studies have shown associations 
between lung cancer and cardiovascular disease (CVD) risk factors related to the 
metabolic syndrome [3,4]. There is also substantial evidence that lipid metabolism 
and innate immunity evolved from common pathways and consequently genes that 
influence lipid traits may also influence inflammation and subsequent cancer 
development [5-7]. Lung cancer is also well-known to be strongly associated with 
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tobacco smoking. Predicated on the hypothesis that investigating shared genetic risk 
factors across these traits could enhance the possibility to identify new genetic loci for 
lung cancer, we used quantile-quantile (Q-Q) plots [8] (Online Methods) to assess 
potential polygenic enrichment of SNPs associated with lung cancer given association 
with each CVD risk factor or smoking phenotypes (Figure 1 and Supplementary 
Figure 1).  
The analysis was based on the TRICL consortium meta-analysis of lung cancer 
GWAS, including 12,160 lung cancer cases and 16,838 controls [2]  (Supplementary 
Table 1); the meta-analysis data of blood lipids from the Global Lipids Genetics 
Consortium (GLGC, including genetic association with triglycerides (TG), and high 
and low density lipoproteins-cholesterol (HDL-C and LDL-C)) from 188,577 subjects [9], of Type 2 diabetes (T2D) from 148,821 subjects [10]  and of body mass index 
(BMI) from 123,865 subjects [11] ; and the meta-analysis of cigarettes per day (CPD) 
and never vs. ever smoking data from the Tobacco, Alcohol and Genetics (TAG) 
consortium, including 74,053 subjects (Supplementary Table 2). The 
Supplementary Materials (available online) contain additional details on the 
contributing studies, statistical analyses and functional tests. 
The Q-Q plots show enrichment between lung cancer and LDL-C and between lung 
cancer and TG blood lipid traits across multiple p-value thresholds up to 10-5 (Figure 
1A-B) verified by an adaptive permutation procedure (Supplementary Table 3). In 
contrast, we observed no significant enrichment (P<0.001) between lung cancer and 
HDL, BMI, T2D or smoking phenotypes (the analysis of smoking excluded the SNP markers mapping to chr15:78,686,690-79,231,478, which are known to be 
associated with lung cancer and smoking [12-13] (Supplementary Table 3, 
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Supplementary Figure 1). Thus we excluded these traits from further analysis.   
Cross-phenotype associated loci between lung cancer and TG and between lung 
cancer and LDL-C were assessed by conjunction false discovery rate (FDR) [8] 
(Supplementary Materials). Because controlling FDR is heavily affected by the 
number of identified SNPs, we pruned SNPs in linkage disequilibrium (LD) (r2>0.8) 
and excluded the major histocompatibility complex (MHC) (genomic position (hg 
19): chr6:29,528,318-33,373,649 [14]), which harbors established lung cancer 
susceptibility SNPs and is known for long range LD. By controlling conjunction 
FDR, we identified one genetic locus at 6p22.1, rs6904596, A>G, Minor Allele 
Frequency in Caucasians=0.094, associated with both lung cancer and blood 
triglycerides (conjunction FDR=0.0124; P=5.5x10-6 for lung cancer; P=1.39x10-5 for 
TG (This locus and additional genetic loci shared between lung cancer and lipid traits 
are shown in Supplementary Table 4 and Supplementary Figures 2-6). This locus 
remained significant also using different thresholds for pruning SNPs in LD 
(Supplementary Table 5). 
We tested this SNP for replication in 6,097 lung cancer cases and 204,657 controls 
from deCODE, Harvard, Holland and Spain (Supplementary Table 6). This locus 
was replicated (Preplication=2.4×10-4) and attained genome-wide significance for lung 
cancer risk in the meta-analysis of discovery and replication data (two-sided 
Pcombined=5.2x10-9, Pheterogeneity=0.91, Table 1). This SNP was also replicated in the 
association with TG in 71,113 independent samples from deCODE and Holland (two-
sided P=0.011, Pcombined=1.34 x 10-6, Table 1).  
The SNP association with lung cancer was mostly driven by the squamous cell 
carcinoma subtype (P=2.8x10-5) and not adenocarcinoma (P=0.06, Supplementary 
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Table 7).   
rs6904596 localizes to 6p22.1 (27,491,299 bp; hg19) and lies 50kb 5' of Zinc Finger 
Protein 184 (ZNF184). It shows expression-QTL in lung tissue [15] with HLA-DRB3 
(β=-6.79, P=1.10x10-11). Additionally, rs7749305, located on chr6:27,446,566 (r2=1 
with rs6904596 in HapMap 3 of Caucasian populations), shows suggestive regulatory 
functions. This SNP showed the strongest association with lung cancer, but was not 
genotyped in the Global Lipid Consortium GWAS. It lies within a DNaseI 
hypersensitive region in small airway epithelial cells (SAEC) and A549 
adenocarcinoma cells (ENCODE) and lies in a region hypomethylated in primary 
Alveolar Epithelial Cells (AEC) from our laboratory (Supplementary Figure 7). 
rs7749305 alternate allele C appears to create ATF3 and HIF1A binding sites. Similar 
findings are evident in adipocytes (ENCODE), extending the pleiotropic association 
between lung cancer and lipid traits to their function in respective tissue types. 
 
Our study emphasizes that pleiotropic analysis of GWAS data of epidemiologically-
related traits can uncover hitherto unidentified genetic associations. Moreover, some GWAS of quantitative traits may be much larger than disease specific GWAS (like in the case of CVD risk factors vs. lung cancer), and thus may improve the likelihood to identify new loci for the disease with the smaller sample size. 
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Table 1.   Association of rs6904596 at 6p22.1 with both lung cancer risk and blood triglycerides’ levels 
 
 
Study 
Lung cancer 
Cases/ 
Controls 
OR 95% CI P-value  Study Triglycerides Individuals 𝜷𝜷 95% CI P-value 
TRICL 12160/16838 1.15 (1.08,1.21) 5.50 x 10-6  GLGC 188577 0.0244 (0.013,0.035) 1.39 x 10-5 
Replication 6097/204657 1.16 (1.07,1.25) 2.4 x 10-4  Replication 71113 0.0290 (0.006,0.051) 1.14 x 10-2 
   deCODE 3865/196658 1.17 (1.06,1.30) 3.05 x 10-3     deCODE 66027 0.0200 (-0.004,0.044) 0.10 
   Harvard 984/ 970 1.18 (0.93,1.50) 0.171     Holland 5086 0.0891 (0.027,0.151) 5.12 x 10-3 
   Holland 687/ 5158 1.15 (0.96,1.37) 0.119       
   Spain 561/ 1871 1.10 (0.88,1.37) 0.40  Combined 259690 0.0253 (0.015,0.035) 1.34 x 10-6 
Combined 18257/ 221495 1.15 (1.10,1.21) 5.2 x 10-9       
PQ-
heterogeneity*    0.92      0.23 
 
* Heterogeneity of effect size across studies was evaluated using the Cochran’s Q statistic
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Figure legends  
 
Figure 1.  Conditional Q-Q plots: LuCa | CVD factors (TG and LDL-C).  
 
‘Conditional Q-Q plot’ of theoretical vs empirical -log10 p-values (corrected for 
genomic control 𝜆𝜆) in lung cancer (LuCa) below the standard GWAS threshold of -
log10 p-values equal to 7.3 (equals p-values above 5 x 10-8) as a function of 
significance of association with (A) triglycerides (TG) and (B) low-density 
lipoprotein (LDL-C) at the level of p < 1, p <0.1, p < 0.01, p < 0.001, p<0.0001, 
p<0.00001 respectively. Dotted lines indicate the theoretical line in case of no 
association.     
